Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.

摘要: Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease cancer patients receiving cardiotoxic treatments. Increases cardiac including troponin natriuretic peptides can be used to guide initiation cardioprotective treatments for during treatment monitor response treatments, they also offer prognostic value. This position statement examines role management patients. The Cardio-Oncology Study Group Heart Failure Association (HFA) European Society Cardiology (ESC) collaboration with Council ESC have evaluated current evidence before, after therapies. characteristics main two discussed, link mechanisms toxicity, their clinical use surveillance anthracycline chemotherapy, trastuzumab HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome immune checkpoint cyclophosphamide radiotherapy. Novel pathways integrating chemotherapy or presented future direction cardio-oncology biomarker research is discussed.